Advertisement

Topics

Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

00:52 EDT 22nd July 2017 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 17,000+

Extremely Relevant

Effect of Adding Cetuximab vs Bevacizumab to Chemotherapy for KRAS Wild-Type Colorectal Cancer

This randomized clinical trial compares the effect of adding bevacizumab vs cetuximab to standard chemotherapy regimens on overall survival among patients with advanced or metastatic KRAS wild-type colorectal cancer.


Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer No Difference, but Not the Same

In the United States in 2017, there are projected to be 135 430 individuals newly diagnosed with colorectal cancer and 50 260 deaths from the disease with 18% to 22% having distant metastatic diseases at the time of diagnosis. Over the past decade or more, significant effort has been devoted to optimize first-line treatment for advanced and metastatic colorectal cancer. It has been established...

The Growing Challenge of Young Adults With Colorectal Cancer

n this review, we address specific issues pertaining to AYA patients with colorectal cancer, including evaluation for hereditary colorectal cancer syndromes, clinicopathologic and biologic features unique to AYA patients with colorectal cancer, treatment outcomes, and survivorship.


Cetuximab vs. Bevacizumab for KRAS Wild-Type Advanced Colorectal Cancer

Survival was similar with either agent when combined with first-line chemotherapy.

Adjuvant Bevacizumab for Operable Gastroesophageal Cancer

Adding bevacizumab to perioperative chemotherapy failed to improve survival.

Adjuvant Bevacizumab for Triple-Negative Breast Cancer

Adding bevacizumab to chemotherapy failed to improve 5-year overall survival.

Study paves way to develop noninvasive diagnostic test for colorectal cancer

The type of bacteria in your gut may help diagnose colorectal cancer. Researchers at Baylor College of Medicine and other institutions have identified specific types of bacteria that seem to be abundant in individuals with colorectal cancer.

Colorectal Diseases Biobank links genetics and colorectal cancer

What if your family's DNA could become the blueprint for your very own precise and personalized treatment for colorectal cancer? Or, better yet, what if it could be used to help doctors screen you earlier for the disease, before it has a chance to strike?

Bevacizumab Improves Responses, PFS in Advanced Head and Neck Cancer

This video highlights results of a phase III randomized trial that tested chemotherapy plus bevacizumab in patients with recurrent or metastatic head and neck cancer.

Early detection of colorectal cancer can save lives

Colorectal cancer is the second leading cause of cancer death for men and women in the United States according to the American Cancer Society.

Genetic Factors and Colorectal Cancer: Know Your Risk

Colorectal cancer is one of several cancers with known genetic risk factors. Because these known factors can be identified through genetic testing, it’s important to understand your risks and to discuss them with your healthcare provider. The following are three hereditary factors that can increase your risk for colorectal cancer: People with a personal or […] The post Genetic Factors and ...

Advancing precision medicine in colorectal cancer

Colorectal cancer (CRC) exemplifies the steady progress we’ve made in cancer prevention and treatment,…

Sessile Serrated Polyps and Colorectal Cancer

To the Editor The comprehensive review by Dr Lieberman and colleagues addressed evolving issues in the field of colorectal cancer screening. However, I take issue with the brief discussion of serrated polyps and their effect on the practice of colorectal cancer screening.

Technology advances help to prevent, lessen impact of colon cancer

Approximately 140,000 people are diagnosed with colorectal cancer in the U.S. each year. March is Colorectal Cancer Awareness Month.

Metastatic Colorectal Cancer: Does Exercise Matter?

Patients with colorectal cancer may be able to lower the risk of the disease worsening and improve their chances of survival with moderate daily exercise, according to new research by investigators at Dana-Farber Cancer Institute. The results of the research contradict the widespread belief that, because the prognosis for patients with metastatic cancer is often poor, […] The post Metastati...

Follow-up of Positive Fecal Test Results

A large body of research demonstrates that colorectal cancer screening is an effective method for reducing colorectal cancer mortality. Screening can detect cancer at an earlier stage, before it becomes symptomatic, and the detection and removal of adenomas can prevent cancer. Rates of colorectal cancer screening had increased until 2010, at which time approximately 60% of eligible US adults parti...

More young people are getting colorectal cancer. What do we do?

After years of declining rates of colorectal cancer (CRC), a study from the American Cancer Society raises the specter that not all is going as well as we would have hoped, especially among younger folks born since 1990. And that raises the question of what the future holds for this frequently preventable form of cancer, […]

New model paves way for immune therapies against colorectal cancer

About 95 percent of colorectal cancers are considered "microsatellite stable" and very few of these cancers respond to immunotherapy, meaning that the vast majority of metastatic colorectal cancer patients are unable to benefit from medicines that activate the immune system against the disease - a strategy that has helped dramatically extend the lives of patients with related cancers. A study pres...

Novartis, Bristol-Myers Squibb evaluate potential metastatic colorectal cancer treatments

Colorectal cancer is the third most common type of cancer in men and the second most common in women, with approximately 1.4 million new diagnoses in 2012. For the same period, approximately 694,000 deaths worldwide were attributed to colorectal cancer. Healthcare solutions provider Novartis is working with pharma company Bristol-Myers Squibb to investigate the safety, [&hellip

AACR: New model paves way for immune therapies against colorectal cancer

(University of Colorado Anschutz Medical Campus) Study presented at AACR 2017 describes a new 'humanized mouse' model of colorectal cancer, allowing researchers to test new drugs and new drug combinations against the disease and potentially opening the door to immunotherapy for the larger, microsatellite-stable population of colorectal cancer patients.

Bevacizumab Does Not Improve Response, Survival in Ovarian Cancer

Adding bevacizumab to neoadjuvant chemotherapy did not improve complete macroscopic response rate or progression-free survival in women with ovarian cancer.

March is Colorectal Cancer Awareness Month: Here are 6 prevention recommendations that confuse association with causation

March is Colorectal Cancer Awareness Month, which the American Institute of Cancer Research is marking with a news release headlined “6 Steps to Prevent Nearly Half of Colorectal Cancer Cases.” The recommendations are said to be “research-based” but that term appears to be used loosely. Here’s why. What’s wrong with issuing sensible lifestyle recommendations? The […]

Investigators Named to Stand Up 2 Cancer’s Colorectal Dream Team

Weill Cornell Medicine and NewYork-Presbyterian have been named to the nonprofit Stand Up 2 Cancer’s Colorectal Dream Team to drive new advances in colorectal cancer research and treatment.

Possible Breakthrough in Colorectal Cancer Drug Development Cited

NewsStemSynergy announces breakthrough in colorectal cancer drug development. Scientists showed that a novel class of Wnt inhibitors, CK1alpha agonists, blocked colorectal cancer growth with minimal gastrointestinal toxicity.

Adults with disabilities screened less often for colorectal cancer

(University of Missouri-Columbia) Colorectal cancer is the fourth most common type of cancer in the United States, with nearly 135,000 cases reported in 2016. The likelihood of surviving colorectal cancer is strongly related to the stage in which it is diagnosed. Researchers from the University of Missouri School of Medicine found that individuals with certain disabilities are less likely to recei...


Quick Search
Advertisement
 

News Quicklinks